The Q3 2026 report shows TRIP.CN stock revenue rose to CAD 1.265M, signalling a partial recovery in sales. We see revenue up 8.3% year‑over‑year while adjusted EBITDA lost CAD 0.711M. The stock trades on the CNQ in Canada at CAD 0.015 with intraday volume jumping to 846,614 shares. This earnings update ties revenue momentum to tighter G&A and ongoing R&D work in psilocybin development.

Earnings snapshot for TRIP.CN stock

Revenue for Q3 2026 was CAD 1.265M, up 8.3% from Q3 2025. Adjusted EBITDA loss widened slightly to CAD 0.711M. EPS is reported at -0.010 and the company flagged continued R&D expenses driving short‑term losses.

TRIP.CN earnings and financials

Red Light Holland reported cash of CAD 9.238M and total assets of CAD 18.200M as at Q3 2026. Market cap sits near CAD 6.34M with 422,531,000 shares outstanding. Key ratios show a current ratio 5.18 and price to book 0.395, signalling ample liquidity against low market valuation.

Operational update and R&D progress

Management reported a second 5kg psilocybin shipment to Irvine Labs for R&D and validation work. The company is pausing AEM shiitake operations to focus capital on psilocybin projects. Distribution efforts grew, with sales through 125+ Netherlands retail stores and expanded U.S. placement talks with Albertsons.

TRIP.CN stock trading and technicals

The stock opened at CAD 0.020, with intraday high CAD 0.020 and low CAD 0.015; last trade CAD 0.015. Volume of 846,614 is 4.11x average, showing short‑term interest. Technicals show 50‑day MA CAD 0.0192 and 200‑day MA CAD 0.0298, and RSI near 46, indicating neutral momentum.

Meyka AI grade and forecast for TRIP.CN stock

Meyka AI rates TRIP.CN with a score out of 100: 63.97 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 and sector comparison, financial growth, key metrics, and analyst signals. Meyka AI’s forecast model projects a yearly price CAD 0.003 versus the current CAD 0.015, implying a model‑based downside near -80.00%. Forecasts are model projections and not guarantees.

Risks and opportunities in the TRIP.CN outlook

Opportunities include scaling R&D into therapeutic channels and retail rollouts in North America and Europe. Risks include regulatory change, shipment quality issues noted in Q3, limited trading liquidity, and continued negative EBITDA. Management is exploring M&A and asset sales which could change capital dynamics.

Final Thoughts

Q3 2026 gives a mixed picture for TRIP.CN stock. Revenue improvement to CAD 1.265M and a CAD 9.238M cash balance support near‑term operations. However, the company posted an adjusted EBITDA loss of CAD 0.711M and continues R&D spending that pressures profitability. Trading shows heavy intraday volume at 846,614 vs average 205,740, which increases volatility. Meyka AI’s forecast model projects CAD 0.003 for the year, implying a -80.00% downside versus the current CAD 0.015. For balanced context, we outline price targets: a conservative base CAD 0.010, a model bear CAD 0.003, and a high‑case recovery CAD 0.030 if R&D commercializes and distribution expands. These are analytic scenarios, not recommendations. We use Meyka AI as an AI‑powered market analysis platform to frame probabilities and stress the need for careful risk sizing if you consider TRIP.CN stock for your portfolio.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.